Buy Recommendation for Jubilant Organosys

Keep buying on Jubilant Organosys with a 12-month target price of Rs 450. Jubilant Organosys' Q1FY09 revenue was marginally above estimates on the sales front driven by higher-than-expected growth in the Industrial and Performance Products (IPP) segment. IPP sales came in at Rs 3 billion, a 28% growth YoY driven by higher price realisations. The quarter also witnessed strong growth in CRAMS and inflows from Draxis Health which was acquired in May 2008 for USD 255 million.Exchange losses of Rs 1 billion on restatement of foreign currency borrowings resulted in a 90% decline in PAT to Rs 128 million as against our estimate of Rs 651 million.